LASA6.82

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹34.2 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)87.6782.7234.6134.61
Receivable Days (DSO)12.553.820.600.60
Payable Days (DPO)64.7034.5040.47117.91
Cash Conversion Cycle (days)35.5252.04-5.26-82.70
Working Capital Turnover-9.509.27-3.97-1.00
Asset Turnover0.691.400.380.38
Cash Conversion (CFO/Net Income)-0.100.190.670.67
CFO/EBITDA0.99-0.450.800.80
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.